US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

39.53

-0.1185-0.30%

Post-market: 39.45-0.0797-0.20%16:10 EDT

Volume:982

Turnover:38.59K

Market Cap:7.91M

PE:- -

High:39.53

Open:39.11

Low:39.11

Close:39.65

52wk High:43.01

52wk Low:24.58

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.50

T/O Rate:0.49%

Dividend:0.32

Dividend Rate:0.81%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study

The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1

THOMSON REUTERS

From Tailored Policies to Universal Coverage: The Long Road Ahead for Brain-Computer Interface Insurance

Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Simply Wall St.

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live

Scholar Rock price target raised to $64 from $58 at Wedbush

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS

Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026

THOMSON REUTERS

Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating

Minhang's Magnetic Pull: How One District Captures Nearly 30% of China's Brain-Computer Interface Sector

Dianthus Therapeutics Director Simon Read Disposes of Common Shares Worth $326,148.9

Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?

Simply Wall St.

Jiangxi's Bold Strategy: Breaking Into Frontier Industries Without Coastal Advantages

Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99

Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says

MT Newswires Live

Praxis Precision Medicines, Inc. : Raymond James Raises Target Price to $945 from $765

THOMSON REUTERS

How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/IBRN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":39.5297,"timestamp":1787601600000,"preClose":39.6482,"halted":0,"volume":982,"hourTrading":{"tag":"盘后","latestPrice":39.45,"preClose":39.5297,"latestTime":"16:10 EDT","volume":6,"amount":237.1782,"timestamp":1787602204712,"change":-0.0797,"changeRate":-0.002016,"amplitude":0},"delay":0,"changeRate":-0.002988786376178603,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Closed","change":-0.1185,"latestTime":"08-24 16:00:00 EDT","open":39.11,"high":39.5297,"low":39.11,"amount":38594,"amplitude":0.010586,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787644800000},"marketStatusCode":5,"adr":0,"exchange":"ARCA","adjPreClose":39.6482,"sharesOutstanding":150000,"nav":39.601587,"aum":7920317.4,"dividendRate":0.008123,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":39.64,"preClose":39.6482,"latestTime":"09:29 EDT","volume":1,"amount":39.64,"timestamp":1787578185971,"change":-0.0082,"changeRate":-0.000207,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":39.45,"preClose":39.5297,"latestTime":"16:10 EDT","volume":6,"amount":237.1782,"timestamp":1787602204712,"change":-0.0797,"changeRate":-0.002016,"amplitude":0},"volumeRatio":0.496562,"impliedVol":0.0464,"impliedVolPercentile":0.0717},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.496562,"shares":200000,"dividePrice":0.3211,"high":39.5297,"amplitude":0.010586,"preClose":39.6482,"low":39.11,"week52Low":24.5795,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":39.5297,"eps":0,"divideRate":0.008123,"volume":982,"delay":0,"ttmEps":0,"open":39.11,"prevYearClose":32.3193,"prevWeekClose":39.6482,"prevMonthClose":36.6044,"prevQuarterClose":38.8263,"fiveDayClose":39.6414,"twentyDayClose":37.7182,"sixtyDayClose":35.6957},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662620199","title":"Alkermes’ Alixorexton Posts Positive Phase 2 Vibrance-1 Results in Narcolepsy Type 1 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2662620199","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662620199?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610625,"startTime":"0","endTime":"0","summary":"Alkermes’ alixorexton posts positive Phase 2 Vibrance-1 results in narcolepsy type 1 studyAlkermes reported publication of positive Phase 2 Vibrance-1 results for alixorexton in adults with narcolepsy type 1 in The Lancet Neurology.Results were previously announced, not newly presented, showing improved daytime wakefulness and sleepiness measures versus placebo.Study also indicated reduced cataplexy at one dose, with broader patient-reported benefits in daily functioning.Safety profile appeared generally well tolerated, with mostly mild-to-moderate adverse events and no serious treatment-emergent events reported.Positive Phase 2 readouts supported the launch of the global Phase 3 Brilliance program testing once-daily and split-dose regimens in narcolepsy types 1 and 2.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL56tjq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","IBRN","PSCH","ALKS","FBT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201993","title":"The Lancet Neurology Publishes Data from Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults with Narcolepsy Type 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201993","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662201993?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:30","pubTimestamp":1787610600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nTUA7VQ936:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","MEDX","ALKS","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135099508","title":"From Tailored Policies to Universal Coverage: The Long Road Ahead for Brain-Computer Interface Insurance","url":"https://stock-news.laohu8.com/highlight/detail?id=1135099508","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135099508?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:31","pubTimestamp":1787574680,"startTime":"0","endTime":"0","summary":"The first-of-its-kind invasive brain-computer interface (BCI) surgery accident insurance policy has officially filled a critical gap in China's clinical translation risk protection, yet the journey...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661222175","title":"Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2661222175","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661222175?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:20","pubTimestamp":1787559646,"startTime":"0","endTime":"0","summary":"Earlier this week, Scholar Rock announced it had removed Catalent Indiana from all commercial fill-finish roles in apitegromab’s U.S. BLA for spinal muscular atrophy, withdrawn and planned to resubmit its European filing with an alternate facility, and secured PMDA alignment to file a Japanese application without new local trials.\nThis set of regulatory and manufacturing moves materially reduces operational risk around apitegromab’s global rollout by shifting to a compliant U.S. facility...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-srrk-is-up-85-after-de-risking-apitegromabs-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/scholar-rock-srrk-is-up-85-after-de-risking-apitegromabs-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","IBRN","AIPO","THNR","SRRK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661292181","title":"Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2661292181","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661292181?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:03","pubTimestamp":1787339001,"startTime":"0","endTime":"0","summary":"Scholar Rock's  latest update further de-risks the global apitegromab regulatory path, given the potential approval in the US and clear view on the Japan registration path, offsetting a delay in Europe, Wedbush said Friday.Earlier, Scholar Rock confirmed removal of Novo Nordisk's  Catalent Indiana as a commercial fill-finish facility from its US biologics license application, and it expects an approval decision from the US Food and Drug Administration by Sept. 30 for apitegromab as a treatment for spinal muscular atrophy.In Europe, Scholar Rock said it withdrew its marketing authorization application following the Catalent inspection issue and plans to resubmit with the new facility. In Japan, no additional clinical studies are needed, allowing a new drug application filing by year-end.Wedbush reiterated its outperform rating on Scholar Rock's stock and raised its price target to $64 from $58.Price: 56.16, Change: +0.91, Percent Change: +1.64","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SRRK","BK4139","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661294877","title":"Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661294877","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661294877?lang=en_us&edition=fundamental","pubTime":"2026-08-22 00:45","pubTimestamp":1787330734,"startTime":"0","endTime":"0","summary":"Price: 56.19, Change: +0.94, Percent Change: +1.70","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661729187","title":"Scholar Rock price target raised to $64 from $58 at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2661729187","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661729187?lang=en_us&edition=fundamental","pubTime":"2026-08-21 23:40","pubTimestamp":1787326815,"startTime":"0","endTime":"0","summary":"Wedbush raised the firm’s price target on Scholar Rock (SRRK) to $64 from $58 and keeps an Outperform rating on the shares. Published first on TheF...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-64-from-58-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-64-from-58-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","THNR","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661442293","title":"Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661442293","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661442293?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:10","pubTimestamp":1787317815,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced it has removed Catalent Indiana (NVO) as a commercial fill-finish facility from its apitegromab Biologics License App...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-removes-catalent-indiana-from-apitegromab-bla-under-fda-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-removes-catalent-indiana-from-apitegromab-bla-under-fda-guidance-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","SRRK","BK4530","THNR","BK4585","BK4007","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661829358","title":"Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2661829358","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661829358?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SRRK","BK4139","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661293583","title":"Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2661293583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661293583?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","THNR","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661129353","title":"Scholar Rock Holding Corporation - Pmda Agrees no Additional Clinical Studies Required; Scholar Rock to Submit Apitegromab Jnda by Ye 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661129353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661129353?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:07","pubTimestamp":1787317634,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0ID:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","BK4139","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661300293","title":"Scholar Rock Withdraws EU Apitegromab Filing After FDA Flags Catalent Indiana Plant with OAI Inspection Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2661300293","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661300293?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:06","pubTimestamp":1787317583,"startTime":"0","endTime":"0","summary":"Scholar Rock withdraws EU apitegromab filing after FDA flags Catalent Indiana plant with OAI inspection ratingScholar Rock removed Catalent Indiana as an apitegromab fill-finish site from its FDA BLA ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL5lyPW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118278464","title":"Minhang's Magnetic Pull: How One District Captures Nearly 30% of China's Brain-Computer Interface Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1118278464","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118278464?lang=en_us&edition=fundamental","pubTime":"2026-08-21 13:40","pubTimestamp":1787290838,"startTime":"0","endTime":"0","summary":"Shanghai's Yunfan Future research team had just finalized their technical blueprint when they received targeted guidance on the application pathway for Class II innovative products. Meanwhile, Jinqi...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","MNTL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660765574","title":"Dianthus Therapeutics Director Simon Read Disposes of Common Shares Worth $326,148.9","url":"https://stock-news.laohu8.com/highlight/detail?id=2660765574","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660765574?lang=en_us&edition=fundamental","pubTime":"2026-08-20 06:03","pubTimestamp":1787177000,"startTime":"0","endTime":"0","summary":"Dianthus Therapeutics director Simon Read disposes of common shares worth $326,148.9Dianthus Therapeutics director Simon Read exercised stock options for 2,778 common shares at USD 18.36 on Aug. 19, 2","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL6vl9N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dianthus Therapeutics Director Simon Read Disposes of Common Shares Worth $326,148.9","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660520417","title":"Should Xenon’s Wider Q2 Losses to Fund Neurology Pipeline Require Action From Xenon (XENE) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2660520417","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660520417?lang=en_us&edition=fundamental","pubTime":"2026-08-19 12:51","pubTimestamp":1787115071,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc. recently reported second-quarter 2026 results, with net loss rising to US$110.74 million and basic loss per share from continuing operations at US$1.11, alongside a six‑month net loss of US$213.04 million and basic loss per share of US$2.28.\nThe widening losses compared with the same periods in 2025 give investors fresh insight into how Xenon is funding its ion-channel neurology pipeline ahead of key clinical and commercial milestones.\nWe will now examine how...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/should-xenons-wider-q2-losses-to-fund-neurology-pipeline-req","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ISBC","BK4139","BK4211","SBIO","XENE","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175067602","title":"Jiangxi's Bold Strategy: Breaking Into Frontier Industries Without Coastal Advantages","url":"https://stock-news.laohu8.com/highlight/detail?id=1175067602","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175067602?lang=en_us&edition=fundamental","pubTime":"2026-08-18 11:01","pubTimestamp":1787022066,"startTime":"0","endTime":"0","summary":"On August 7, 2026, the 15th Provincial Committee's 10th Plenary Session convened in Nanchang, followed by a collective study session of the Provincial Party Committee's Theoretical Learning Center...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","WDRN","IQM","RTOO","PBOT","UBOT","MNTL","ROBT","HDRO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660430568","title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2660430568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660430568?lang=en_us&edition=fundamental","pubTime":"2026-08-18 06:54","pubTimestamp":1787007262,"startTime":"0","endTime":"0","summary":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sells 7,576 shares for $374,301.99Alkermes SVP, Chief Commercial Officer Christian Todd Nichols sold 7,576 ordinary shares on Aug. 17, 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDLbv4Lk0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes SVP, Chief Commercial Officer Christian Todd Nichols Sells 7,576 Shares for $374,301.99","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSCH","ALKS","MEDX","IBRN","BK4139","PSIL","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660043669","title":"Praxis Precision Medicines Could Be Approaching 'Perfect Trifecta,' Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2660043669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660043669?lang=en_us&edition=fundamental","pubTime":"2026-08-17 23:21","pubTimestamp":1786980102,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) could be approaching an unprecedented regulatory stretch, with four potential approvals across three drugs within roughly 12 months, a potential \"perfect trifecta,\" O","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","IBRN","OPY","IE00B4R5TH58.HKD","PRAX","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0009355771.USD","BK4127","IE00BJJMRZ35.SGD","LU0109394709.USD","LU0320765992.SGD","BK4139","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484118","title":"Praxis Precision Medicines, Inc. : Raymond James Raises Target Price to $945 from $765","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484118?lang=en_us&edition=fundamental","pubTime":"2026-08-17 19:10","pubTimestamp":1786965021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nFWN44E0K1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJT1NW94.SGD","BK4139","LU0889565916.HKD","PRAX","IBRN","IE00B4R5TH58.HKD","IE0009355771.USD","IE0002141913.USD","LU0109394709.USD","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659173150","title":"How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2659173150","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659173150?lang=en_us&edition=fundamental","pubTime":"2026-08-15 21:21","pubTimestamp":1786800069,"startTime":"0","endTime":"0","summary":"In early August 2026, Scholar Rock Holding Corporation reported that its second-quarter net loss was US$109.9 million, slightly lower than a year earlier, while its six-month net loss widened to US$215.41 million and loss per share stayed broadly similar.\nAt the same time, the company highlighted that its apitegromab biologics license application for spinal muscular atrophy remains under active FDA review with two independent fill-finish facilities prepared to support potential approval and...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/how-investors-are-reacting-to-scholar-rock-srrk-dual-fill-fi","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-srrk/scholar-rock-holding/news/how-investors-are-reacting-to-scholar-rock-srrk-dual-fill-fi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","IBRN","BK4585","LABU","ISBC","BK4588","SRRK","THNR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}